In vivo assays demonstrated an enhanced ability for the SM-LPN-CD44 nanoparticles to deliver salinomycin to PCSC compared to non-targeted nanoparticles, with the SM-LPN-CD44 nanoparticles also showing a significant decrease in CD44-positive cells and drug concentration needed to inhibit 50% of tumor growth (IC50) [120]. Here, CD44 is linked to neoplasm.